18591-70-3

Usage

Uses

Used in Medicinal Chemistry:
6-METHYL[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-8-OL is used as a chemical entity for the development of new pharmaceuticals due to its unique structure and potential biological activity. Its heterocyclic nature may offer specific binding affinities and interactions with biological targets, making it a candidate for drug discovery and design.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6-METHYL[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-8-OL is utilized as a research compound to explore its potential therapeutic effects. Further studies are required to understand its pharmacological properties, mechanism of action, and safety profile, which could lead to its application in the treatment of various diseases and conditions.

InChI:InChI=1/C6H6N4O/c1-4-2-5(11)6-8-7-3-10(6)9-4/h2-3,11H,1H3

Upstream product

• 584-13-4 4-amino-1,2,4-triazole 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 28593-25-1 8-chloro-6-methyl-s-triazolo<4,3-b>pyridazine 
• 1185324-25-7 N-(4-methoxyphenylethyl)-6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 
• 1569869-39-1 N-(4-fluorophenylethyl)-6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 
• 93865-76-0 N-phenethyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 
• 1569869-79-9 N-(4-phenylpropyl)-6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 
• 950254-11-2 N-(4-methoxybenzyl)-6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 
• 876901-53-0 N-benzyl-6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 
• 1569869-59-5 N-(4-aminophenethyl)-6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 
• 1569869-54-0 4-(2-(6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenyl benzoate 
• 1569869-46-0 4-(2-(6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol 
• 878722-08-8 N-(4-chlorophenylethyl)-6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 

Relevant academic research and scientific papers

Preparation and application of triazole heterocyclic compound containing heteroaryl amide structure

The invention discloses a triazole heterocyclic compound containing a heteroaryl amide structure, a geometrical isomer of triazole heterocyclic compound containing the heteroaryl amide structure and pharmacologically acceptable salt, hydrate, solvate or p

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors

Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4] triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.

Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against plasmodium falciparum dihydroorotate dehydrogenase

Plasmodium falciparum causes approximately 1 million deaths annually. However, increasing resistance imposes a continuous threat to existing drug therapies. We previously reported a number of potent and selective triazolopyrimidine-based inhibitors of P.